CADTH Reimbursement Review - Provisional Funding Algorithm - Indication: Adult B-Cell Precursor Acute Lymphoblastic

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials. [...] This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceed ings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] The purpose of this provisional funding algorithm is to incorporate the latest CADTH recommendation for brexucabtagene autoleucel (Tecartus) for the treatment of adult patients with released or refractory B-cell precursor acute lymphoblastic leukemia. [...] In the relapse or refractory setting, the third line options for patients who have received either chemotherapy, inotuzumab ozogamicin or blinatumomab are chemotherapy, brexu-cel for adults 18 years and older, or tisa-cel for adults up to 25 years with or without TKI. [...] The purpose of this provisional funding algorithm is to incorporate the latest CADTH recommendation for brexucabtagene autoleucel (Tecartus) for the treatment of adult patients with released or refractory B-cell precursor acute lymphoblastic leukemia....